Federal News Update: AMRC and C3TI, and Trump’s FY2027 Budget Request
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
Federal News Update: FDA Real-Time Trials and Congressional Reform Efforts Gain Momentum
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
Federal Health Policy Update: Funding, FDA AI, and Drug Supply Chain Shifts
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
AMRC welcomes Panthera and ObjectiveHealth as members
The Association of Multisite Research Corporations (AMRC) today announces that Panthera and ObjectiveHealth have joined the organisation, bringing total membership to 19 multisite clinical research corporations (MCRCs), up from 14 members just 12 months ago.
Federal News Update: FDA Trial Policy Changes and Q2 Health Policy Outlook
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
Federal News Update: FDA RTF decision, FY26 funding secured, and FDA Modernization Act 3.0
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
Federal News Update: FDA Releases Guidance on Modernizing Statistical Methods in Clinical Trials
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
AMRC publishes 2026 positioning paper
At the beginning of 2025, AMRC set out to champion the multisite clinical research corporation (MCRC) model and to ensure that Sponsors, CROs, policymakers, and the wider industry understood its advantages.
Federal News Update: White House Seeks Input on Science and Research and President Trump Announces Genesis Mission
As part of its CDER modernization implementation, the FDA also announced a new leader of its Office of Nonprescription Drugs (ONPD). Karen Murry, M.D., will serve as director of ONPD.
Federal News Update: Senate votes to reopen the federal government, FDA Announces National Priority Voucher Awards…
For Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials.
